论文部分内容阅读
目的探讨布地奈德联合复方异丙托溴铵雾化吸入辅助治疗支气管哮喘的临床疗效。方法将76例支气管哮喘患者随机分为观察组(39例)和对照组(37例)。对照组采用吸氧、氨茶碱、激素等综合治疗,合并感染者加用抗生素;观察组则在对照组治疗的基础上加用雾化吸入布地奈德2mg和复方异丙托溴胺2.5ml,2～3次/d,治疗5d后进行临床疗效评估。结果观察组在喘憋、咳嗽、哮鸣音消失时间及住院天数均优于对照组,临床控制率优于对照组。结论布地奈德联合复方异丙托溴铵雾化吸入治疗支气管哮喘,其临床疗效确切。
Objective To investigate the clinical efficacy of budesonide combined with ipratropium bromide inhalation in the treatment of bronchial asthma. Methods 76 patients with bronchial asthma were randomly divided into observation group (39 cases) and control group (37 cases). In the control group, inhaled oxygen, aminophylline, hormones and other comprehensive treatment were combined with antibiotics plus antibiotics; the observation group was treated with inhalation of budesonide 2mg and compound ipratropium bromide 2.5ml , 2 ~ 3 times / d, 5d after treatment for clinical efficacy evaluation. Results The observation group was better than the control group in wheezing, cough, wheezing disappearance time and days of hospitalization, and the clinical control rate was better than that of the control group. Conclusion Budesonide combined with ipratropium bromide inhalation treatment of bronchial asthma, the clinical efficacy of the exact.